Cipla has acquired final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from america Food and Drug Administration (USFDA).
Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated common therapeutic equivalent model of Sunovion Pharmaceuticals Inc.’s Brovana.
Brovana is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for:
Long-term, two times every day (morning and night) administration in the preservation remedy of bronchoconstriction in sufferers with continual obstructive pulmonary disorder (COPD), which includes continual bronchitis and emphysema.
According to IQVIA (IMS Health), Brovana had US sales of about $438M for the 12-month period finishing April 2021.
Bazaarinformation team has many years of experience, covering the physical and future commodities markets with prominent commodity & equity trading advising which shines further with extensive network to get research from ground levels to generate proper reporting and movements. We are able to get evens out of odds in volatile markets and stockings. ...
